• español 
    • español
    • English
    • français
  • FacebookPinterestTwitter
  • español
  • English
  • français
Ver ítem 
  •   DIGIBUG Principal
  • 1.-Investigación
  • Departamentos, Grupos de Investigación e Institutos
  • Grupo: Síntesis Orgánica (FQM339)
  • FQM339 - Artículos
  • Ver ítem
  •   DIGIBUG Principal
  • 1.-Investigación
  • Departamentos, Grupos de Investigación e Institutos
  • Grupo: Síntesis Orgánica (FQM339)
  • FQM339 - Artículos
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

A P(V) platform for oligonucleotide synthesis

[PDF] Articulo principal (2.331Mb)
Identificadores
URI: https://hdl.handle.net/10481/101157
DOI: 10.1126/science.abi9727
Exportar
RISRefworksMendeleyBibtex
Estadísticas
Ver Estadísticas de uso
Metadatos
Mostrar el registro completo del ítem
Autor
Huang, Yazhong; Knouse, Kyle W.; Qiu, Shenjie; Hao, Wei; Vantourout, Julien C.; Zheng, Bin; Mercer, Stephen E.; Lopez-Ogalla, Javier; Narayan, Rohan; Olson, Richard E.; Blackmond, Donna G.; Eastgate, Martin D.; Schmidt, Michael A.; McDonald, Ivar M.; Baran, Phil S.; Muñoz Padial, Natalia
Editorial
American Association for the Advancement of Science: AAAS, USA.
Fecha
2021-09-10
Referencia bibliográfica
Science, 2021, 373, 1265–1270
Patrocinador
We thank D.-H. Huang and L. Pasternack (Scripps Research) for assistance with NMR spectroscopy; J. Chen (Automated Synthesis Facility, Scripps Research) for purification of compounds and acquisition of HRMS data; A. L. Rheingold, C. E. Moore, and M. Gembicky (UCSD) for x-ray analysis; and S. Mukherjee (BMS) for calculating the process mass intensity. Funding: This work was supported by Bristol Myers Squibb, NIGMS (GM106210), NIH (grant number GM-118176), Marie Skłodowska-Curie Global Fellowships (749359-EnanSET, N.M.P) within the European Union research and innovation framework program (2014-2020), and the NSF SURF Program (TSRI, R.N).
Resumen
The promise of gene-based therapies is being realized at an accelerated pace, with more than 155 active clinical trials and multiple U.S. Food and Drug Administration approvals for therapeutic oligonucleotides, by far most of which contain modified phosphate linkages. These unnatural linkages have desirable biological and physical properties but are often accessed with difficulty using phosphoramidite chemistry. We report a flexible and efficient [P(V)]–based platform that can install a wide variety of phosphate linkages at will into oligonucleotides. This approach uses readily accessible reagents and can install not only stereodefined or racemic thiophosphates but any combination of (S, R or rac)–PS with native phosphodiester (PO2) and phosphorodithioate (PS2) linkages into DNA and other modified nucleotide polymers. This platform easily accesses this diversity under a standardized coupling protocol with sustainably prepared, stable P(V) reagents.
Colecciones
  • FQM339 - Artículos

Mi cuenta

AccederRegistro

Listar

Todo DIGIBUGComunidades y ColeccionesPor fecha de publicaciónAutoresTítulosMateriaFinanciaciónPerfil de autor UGREsta colecciónPor fecha de publicaciónAutoresTítulosMateriaFinanciación

Estadísticas

Ver Estadísticas de uso

Servicios

Pasos para autoarchivoAyudaLicencias Creative CommonsSHERPA/RoMEODulcinea Biblioteca UniversitariaNos puedes encontrar a través deCondiciones legales

Contacto | Sugerencias